Creation of live influenza vaccines with the use of site-specific mutagenesis

The introduction of genetic engineering methods into the production of live influenza vaccines provides significant optimization of separate stages of this process. In recent years, special attention has been paid to a method based on the direct incorporation of well-known and well-studied mutations into the genome of epidemic variants of influenza virus. Such virus obtains the ts- and att phenotypes and can be used for the production of live influenza vaccines. The article discusses the applications of this approach and problems associated with its use in medical and veterinary vaccinology.